Stockreport

Chiesi Global Rare Diseases and Protalix BioTherapeutics Announce Validation of Variation Submission by European Medicines Agency for pegunigalsidase alfa [Yahoo! Finance]

Protalix BioTherapeutics, Inc. (DE)  (PLX) 
PDF PARMA, Italy and CARMIEL Israel Dec. 9, 2024 /PRNewswire/ -- Chiesi Global Rare Diseases, a business unit of the Chiesi Group established to deliver innovative therapie [Read more]